Six1基因甲基化在肝癌病情及预后评估中的价值

Value of Six1 gene methylation in the evaluation of liver cancer condition and prognosis

目的检测肝癌中Six1基因甲基化并研究其在肝癌病情及预后评估中的价值。方法采用甲基化特异性PCR检测肝癌患者肝癌组织、癌旁正常组织和慢性乙型肝炎患者肝组织Six1基因甲基化并比较其差异,分析肝癌患者不同临床病理因素中Six1基因甲基化差异,比较肝癌患者中Six1基因甲基化患者和未甲基化患者预后的差异。结果肝癌患者肝癌组织Six1基因甲基化率显著低于癌旁正常组织和慢性肝炎患者(27.5%vs 97.5%、97.5%,P均<0.05)。肝癌患者肝癌组织Six1基因甲基化在分化程度、肿瘤大小、门脉癌栓、远处转移和TNM分期方面的差异均有统计学意义(P均<0.05)。肝癌患者中Six1基因甲基化患者R0切除率和无进展生存时间均高于未甲基化患者,3年死亡率低于未甲基化患者(P均<0.05)。肝癌细胞系HepG2、C3A和SMMC-7721中Six1基因均检测到处于非甲基化状态,表明Six1基因处于非甲基化灭活状态。结论Six1基因低甲基化激活与肝癌发病机制密切相关,在其病情及预后评估中具有重要价值。

Objective To study the value of Six1 gene methylation in the evaluation of liver cancer condition and prognosis.Methods The methylations of Six1 gene promoter in liver cancer tissue,paracancerous tissue and normal tissue in chronic hepatitis were detected and compared by methylation specific PCR.The relationship between clinic pathological factors and Six1 gene promoter methylation was analyzed.The prognosis between cases with Six1 gene promoter methylation and unmethylation was compared.Results The methylation rate in liver cancer tissue was significantly lower than that in paracancerous tissue and chronic hepatitis(P<0.05).The differences of Six1 gene promoter methylation rates in extent of differentiation,tumor size,portal vein tumor thrombus,distant metastasis,and TNM stage were statistics significant(P<0.05).The R0 operation rate and disease-free survival time in liver cancer patients with Six1 gene promoter methylation were significantly higher than those in patients with unmethylation,while 3-year mortality rate was lower(P<0.05).Conclusion Six1 gene promoter hypomethylation correlates with the pathogenesis of liver cancer,which could act as a biomarker in the assessment of disease condition and prognosis.